NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: McMaster University
Conditions: Airway Auto Immunity in Asthma
Countries: Canada
It has been observed that certain section of patients having severe to moderate Asthma, do not benefit from oral corticosteroids and IL-5 blocking biologics. There is increasing evidence that Airway auto immunity may be responsible for this poor response to treatment. It has been seen in earlier study done at Nair lab that these patients might benefit from Dupilumab, a biologic blocking IL-13/ IL-4. IL-13/IL-4 are the cytokines responsible for increased inflammation in these Asthmatics. The hypothesis is that blocking IL-13/IL-4 will also reduce the airway auto immunity which can be measured by comparing the auto immune markers in airway at baseline (before starting Dupilumab) and 16 weeks (after 4 months of Dupilumab treatment.
Sex: ALL
Age: 18 Years to 100 Years
Study type: OBSERVATIONAL
Inclusion Criteria: * Prior to the beginning of the study, patients must be willing and fully capable to provide written informed consent * Subjects must be able and willing to comply with the study protocol * Asthma diagnosed by a respiratory physician ≥ 36 months prior to study enrollment based on the Global Initiative for Asthma (GINA) 2014 guidelines * Patients referred or routinely followed for asthma by Dr. Nair * Clinical indication to prescribe dupilumab or will enter a clinical trial where patient will receive drug for at least 4 months * ICS dose ≥ 500 mcg of fluticasone equivalent/day, and/or daily prednisone Exclusion Criteria: * Current smoker defined as having smoked at least one cigarette (or pipe, cigar, or marijuana) per day for ≥ 30 days within the three months prior to screening * Ex-smokers with ≥ 20 pack-year smoking history * Current pregnancy or lactation * Treatment with anti- Immunoglobulin E (IgE), anti-IL-5, or anti-IL-5 Receptor targeted therapy currently or within three months prior to Visit 1 * Any prior medical conditions or treatment history that the physician deems unfit (including but not restricted to chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, tuberculosis).
- Hamilton, Ontario, Canada